美西律（Kö 1173）用于室性心律失常的治疗。 - Suppr

Suppr

超能文献

Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

作者信息

Campbell N P, Kelly J G, Shanks R G, Chaturvedi N C, Strong J E, Pantridge J F

出版信息

Lancet. 1973 Aug 25;2(7826):404-7. doi: 10.1016/s0140-6736(73)92271-x.

DOI:10.1016/s0140-6736(73)92271-x

PMID:4124890

Abstract

摘要

相似文献

Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Lancet. 1973 Aug 25;2(7826):404-7. doi: 10.1016/s0140-6736(73)92271-x.

Treatment of ventricular arrhythmias with mexiletine (Kö 1173).

Lancet. 1973 Aug 25;2(7826):399-404. doi: 10.1016/s0140-6736(73)92270-8.

Lidocaine (Xylocaine) as an anti-arrhythmic agent.

Med Lett Drugs Ther. 1971 Jan 8;13(1):1-2.

Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report.

Int J Cardiol. 1985 Mar;7(3):303-6. doi: 10.1016/0167-5273(85)90056-7.

Lidocaine as an antiarrhythmic Experience in 68 patients.

Acta Med Scand. 1969 Apr;185(4):297-302.

Mexiletine and tocainide: does response to one predict response to the other?

J Am Coll Cardiol. 1986 Feb;7(2):338-43. doi: 10.1016/s0735-1097(86)80502-2.

Aprindine (AC 1802), a new anti-arrhythmic drug.

Acta Cardiol. 1973;28(2):145-65.

Effects of KO 1173 on ventricular arrhythmias.

Br Heart J. 1973 May;35(5):559.

Long-term treatment of ventricular arrhythmias with oral mexiletine.

Am Heart J. 1976 Jan;91(1):58-65. doi: 10.1016/s0002-8703(76)80435-8.

Ko 1173--an effective new antiarrhythmic drug.

Br Heart J. 1973 May;35(5):558-9.

引用本文的文献

Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review.

Europace. 2022 Nov 22;24(11):1809-1823. doi: 10.1093/europace/euac087.

The influence of urinary pH on the elimination of mexiletine.

Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x.

The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH.

Br J Clin Pharmacol. 1974 Feb;1(1):86-7. doi: 10.1111/j.1365-2125.1974.tb00214.x.

Therapeutic drug monitoring of antiarrhythmic drugs.

Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004.

Clinical pharmacokinetics of mexiletine.

Clin Pharmacokinet. 1999 Nov;37(5):361-84. doi: 10.2165/00003088-199937050-00002.

Combined mexiletine and propranolol treatment of refractory ventricular tachycardia.

Br Med J. 1980 Aug 2;281(6236):357-8. doi: 10.1136/bmj.281.6236.357.

Plasma mexiletine concentrations following combined oral and intramuscular administration.

Eur J Clin Pharmacol. 1981 Mar;19(4):301-4. doi: 10.1007/BF00562808.

Pharmacokinetics of mexiletine in renal insufficiency.

Br J Clin Pharmacol. 1982 Sep;14(3):431-5. doi: 10.1111/j.1365-2125.1982.tb02003.x.

Enhanced metabolism of mexiletine after phenytoin administration.

Br J Clin Pharmacol. 1982 Aug;14(2):219-23. doi: 10.1111/j.1365-2125.1982.tb01965.x.

Therapeutic drug monitoring of antiarrhythmic agents.

Clin Pharmacokinet. 1982 Mar-Apr;7(2):125-48. doi: 10.2165/00003088-198207020-00003.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Lancet. 1973 Aug 25;2(7826):404-7. doi: 10.1016/s0140-6736(73)92271-x.

Treatment of ventricular arrhythmias with mexiletine (Kö 1173).

Lancet. 1973 Aug 25;2(7826):399-404. doi: 10.1016/s0140-6736(73)92270-8.

Lidocaine (Xylocaine) as an anti-arrhythmic agent.

Med Lett Drugs Ther. 1971 Jan 8;13(1):1-2.

Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report.

Int J Cardiol. 1985 Mar;7(3):303-6. doi: 10.1016/0167-5273(85)90056-7.

Lidocaine as an antiarrhythmic Experience in 68 patients.

Acta Med Scand. 1969 Apr;185(4):297-302.

Mexiletine and tocainide: does response to one predict response to the other?

J Am Coll Cardiol. 1986 Feb;7(2):338-43. doi: 10.1016/s0735-1097(86)80502-2.

Aprindine (AC 1802), a new anti-arrhythmic drug.

Acta Cardiol. 1973;28(2):145-65.

Effects of KO 1173 on ventricular arrhythmias.

Br Heart J. 1973 May;35(5):559.

Long-term treatment of ventricular arrhythmias with oral mexiletine.

Am Heart J. 1976 Jan;91(1):58-65. doi: 10.1016/s0002-8703(76)80435-8.

Ko 1173--an effective new antiarrhythmic drug.

Br Heart J. 1973 May;35(5):558-9.

引用本文的文献

Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review.

Europace. 2022 Nov 22;24(11):1809-1823. doi: 10.1093/europace/euac087.

The influence of urinary pH on the elimination of mexiletine.

Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x.

The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH.

Br J Clin Pharmacol. 1974 Feb;1(1):86-7. doi: 10.1111/j.1365-2125.1974.tb00214.x.

Therapeutic drug monitoring of antiarrhythmic drugs.

Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004.

Clinical pharmacokinetics of mexiletine.

Clin Pharmacokinet. 1999 Nov;37(5):361-84. doi: 10.2165/00003088-199937050-00002.

Combined mexiletine and propranolol treatment of refractory ventricular tachycardia.

Br Med J. 1980 Aug 2;281(6236):357-8. doi: 10.1136/bmj.281.6236.357.

Plasma mexiletine concentrations following combined oral and intramuscular administration.

Eur J Clin Pharmacol. 1981 Mar;19(4):301-4. doi: 10.1007/BF00562808.

Pharmacokinetics of mexiletine in renal insufficiency.

Br J Clin Pharmacol. 1982 Sep;14(3):431-5. doi: 10.1111/j.1365-2125.1982.tb02003.x.

Enhanced metabolism of mexiletine after phenytoin administration.

Br J Clin Pharmacol. 1982 Aug;14(2):219-23. doi: 10.1111/j.1365-2125.1982.tb01965.x.

Therapeutic drug monitoring of antiarrhythmic agents.

Clin Pharmacokinet. 1982 Mar-Apr;7(2):125-48. doi: 10.2165/00003088-198207020-00003.